Validation of the non-motor symptoms questionnaire (NMS-Quest)

Author(s): Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, et al.


Background:Although non-motor manifestations of Parkinson's disease are common and can cause severe disability, they are often under-recognized, leading to missed treatment opportunities. Screening tools for non-motor symptoms are urgently needed. Recently a 30-item screening Non Motor Symptoms Questionnaire was developed. Although some psychometric properties have been evaluated, sensitivity and specificity of the questionnaire have not been systematically assessed.

Methods:Parkinson patients completed Non Motor Symptoms Questionnaire, then underwent a gold-standard clinical evaluation of non-motor symptoms and signs that included extensive standardized questionnaires, cognitive/behavioural assessment, and neurological examination to determine whether each manifestation was present or absent. The sensitivity and specificity of each non-motor symptom, in relation to the gold-standard were estimated.

Results:For the 70 participants, the mean age was 66.7+/-9.3, 64% were men, and disease duration was 3.8+/-2.8 years. From the gold-standard evaluation, the prevalence of non-motor manifestations ranged from 8.7% (hallucinations) to 78.3% (nocturia). The mean sensitivity of all Non Motor Symptoms was 63.4%. This varied considerably among different manifestations, ranging from 24% (sleepiness, hyposmia) to 100% (diplopia). By restricting analysis to clinically significant non-motor problems (i.e. those serious enough to warrant treatment), the mean sensitivity increased to 71.8%. The specificity for most items was high, with an overall mean specificity of 88.5%.

Conclusions:For many non-motor manifestations Non Motor Symptoms Questionnaire is an effective screen; however, for manifestations such as somnolence, olfactory loss and apathy, sensitivity is suboptimal. Overall, this questionnaire can be a useful clinical tool for screening non-motor problems in an office setting.

Similar Articles

A survey of pain in idiopathic Parkinson's disease

Author(s): Lee MA, Walker RW, Hildreth TJ, Prentice WM

Depression and pain comorbidity: a literature review

Author(s): Bair MJ, Robinson RL, Katon W, Kroenke K

Pain is common in Parkinson's disease

Author(s): Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M

Low dopamine D(2) receptor binding potential in social phobia

Author(s): Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, et al.

Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients

Author(s): Erro R, Santangelo G, Picillo M, Vitale C, Amboni M, et al.

Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD--a comparison of neuropsychological effects

Author(s): Smeding HM, Esselink RA, Schmand B, Koning-Haanstra M, Nijhuis I, et al.

Pain in Parkinson's disease

Author(s): Ford B

CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice

Author(s): Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, et al.

Pain in Parkinson's disease

Author(s): Ha AD, Jankovic J

Pain sensitivity and clinical progression in Parkinson's disease

Author(s): Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, et al.